PrimeC Safe, Well-tolerated; Earns US Patent Allowance

PrimeC Safe, Well-tolerated; Earns US Patent Allowance

288574

PrimeC Safe, Well-tolerated; Earns US Patent Allowance

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and showed signs of slowing disease progression in patients, findings from a recently-completed Phase 2a study show. All 15 participants in the NST002 clinical trial (NCT04165850) have chosen to continue receiving the treatment in an extension study, NeuroSense Therapeutics announced in a press release. As part of the company’s plans to make this treatment available to ALS patients within the next four years,…

You must be logged in to read/download the full post.